Immune cell extravasation in an organ-on-chip to model lung inflammation

Os, Lisette van; Yeoh, Jeremy; Witz, Guillaume; Ferrari, Dario; Krebs, Philippe; Chandorkar, Yashoda; Zeinali, Soheila; Sengupta, Arunima; Guénat, O.

doi:10.1016/j.ejps.2023.106485

Cited by 2 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While most disease-related inflammatory lung-on-chip models focus on SARS-CoV-2, other viral infections have also been studied. PBMCs in a lung-on-chip model of rare acute respiratory distress syndrome (ARDS) displayed extravasation from one chip channel to another that was dependent on the presence of an endothelial barrier, ECM density/stiffness, and the flow profile ( 31 ). Bidirectional flow delayed the extravasation of immune cells compared to unidirectional flow, highlighting the importance of organ-specific dynamic flow conditions.…”

Section: Organ Barriersmentioning

confidence: 99%

In vitro immunity: an overview of immunocompetent organ-on-chip models

Morrison,

Sjoerds,

Vonk

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Impressive advances have been made to replicate human physiology in vitro over the last few years due to the growth of the organ-on-chip (OoC) field in both industrial and academic settings. OoCs are a type of microphysiological system (MPS) that imitates functional and dynamic aspects of native human organ biology on a microfluidic device. Organoids and organotypic models, ranging in their complexity from simple single-cell to complex multi-cell type constructs, are being incorporated into OoC microfluidic devices to better mimic human physiology. OoC technology has now progressed to the stage at which it has received official recognition by the Food and Drug Administration (FDA) for use as an alternative to standard procedures in drug development, such as animal studies and traditional in vitro assays. However, an area that is still lagging behind is the incorporation of the immune system, which is a critical element required to investigate human health and disease. In this review, we summarise the progress made to integrate human immunology into various OoC systems, specifically focusing on models related to organ barriers and lymphoid organs. These models utilise microfluidic devices that are either commercially available or custom-made. This review explores the difference between the use of innate and adaptive immune cells and their role for modelling organ-specific diseases in OoCs. Immunocompetent multi-OoC models are also highlighted and the extent to which they recapitulate systemic physiology is discussed. Together, the aim of this review is to describe the current state of immune-OoCs, the limitations and the future perspectives needed to improve the field.

show abstract

Section: Organ Barriersmentioning

confidence: 99%

In vitro immunity: an overview of immunocompetent organ-on-chip models

Morrison,

Sjoerds,

Vonk

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Engineering Biomaterials to Model Immune‐Tumor Interactions In Vitro

Skirzynska,

Xue,

Shoichet

2024

Advanced Materials

View full text Add to dashboard Cite

Engineered biomaterial scaffolds are becoming more prominent in research laboratories to study drug efficacy for oncological applications in vitro, but do they have a place in pharmaceutical drug screening pipelines? The low efficacy of cancer drugs in phase II/III clinical trials suggests that there are critical mechanisms not properly accounted for in the pre‐clinical evaluation of drug candidates. Immune cells associated with the tumour may account for some of these failures given recent successes with cancer immunotherapies; however, there are few representative platforms to study immune cells in the context of cancer as traditional 2D culture is typically monocultures and humanized animal models have a weakened immune composition. Biomaterials that replicate tumour microenvironmental cues may provide a more relevant model with greater in vitro complexity. In this review, we explore the pertinent microenvironmental cues which drive tumour progression in the context of the immune system, discuss how these cues can be incorporated into hydrogel design to culture immune cells, and describe progress toward precision oncological drug screening with engineered tissues.This article is protected by copyright. All rights reserved

show abstract

Immune cell extravasation in an organ-on-chip to model lung inflammation

Cited by 2 publications

References 58 publications

In vitro immunity: an overview of immunocompetent organ-on-chip models

In vitro immunity: an overview of immunocompetent organ-on-chip models

Engineering Biomaterials to Model Immune‐Tumor Interactions In Vitro

Contact Info

Product

Resources

About